Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101990 | 0.78 | MEN1 (0.55) | MEN1KMT2AHRH3KCNH2 | |
| SCHEMBL762701 | 0.76 | MAOA (0.50) | — | |
| SCHEMBL19844796 | 0.76 | MAOA (0.50) | — | |
| SCHEMBL26192019 | 0.72 | MEN1 (0.50) | MEN1KMT2AHRH3KCNH2DRD4 | |
| SCHEMBL315647 | 0.71 | BRD4 (0.54) | BRD4CREBBP | |
| SCHEMBL13267985 | 0.70 | NOTUM (0.39) | MEN1KMT2AHRH3KCNH2 | |
| SCHEMBL13711153 | 0.70 | NOTUM (0.39) | MEN1KMT2AHRH3KCNH2 | |
| SCHEMBL1083820 | 0.69 | MAOA (0.57) | MEN1KMT2AHRH3KCNH2DRD4 | |
| SCHEMBL30561536 | 0.69 | MAOA (0.57) | MEN1KMT2AHRH3KCNH2DRD4 | |
| Methane SCHEMBL27448869 | 0.69 | BRD4 (0.52) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | MEN1 128/4885KMT2A 1279/4885HRH3 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.